Chennai Meenakshi Multispeciality Hospital Limited’s Board of Directors convened on August 11, 2026, to review and approve the unaudited financial results for the quarter ended June 30, 2026. The meeting also saw the significant appointment of Dr. Thanigai Vendan Moorrthy as Chief Executive Officer and Key Managerial Personnel for a five-year term. Additionally, four new independent directors were appointed to the board.
Board Approves Q1 FY27 Financials and Key Appointments
The Board of Directors of Chennai Meenakshi Multispeciality Hospital Limited held a meeting on August 11, 2026, during which they considered and approved the unaudited financial results for the quarter ending June 30, 2026. The Limited Review Report from the statutory auditors was also submitted and approved as part of these results. These financial statements provide a snapshot of the company’s performance for the first quarter of the fiscal year 2026-2027.
New Chief Executive Officer Appointed
Following the recommendation of the Nomination and Remuneration Committee, the Board approved the appointment of Dr. Thanigai Vendan Moorrthy as the new Chief Executive Officer (CEO). Dr. Moorrthy will also serve as Key Managerial Personnel (KMP) for a term of five consecutive years, effective from August 11, 2026. His extensive experience as a Senior Anesthesiologist and Healthcare Executive with over 15 years of clinical and leadership expertise was highlighted in his profile.
Independent Directors Join the Board
The Board further announced the appointment of four new Independent Directors. These appointments are effective from August 11, 2026, and are subject to shareholder approval at the ensuing Annual General Meeting:
- Mr. A F Simeon Telfer as an Additional Non-Executive Independent Director for a term of five years.
- Mr. R V Ramanuja Bharathi as an Additional Non-Executive Independent Director for a term of five years.
- Ms. Sindu Chawla as an Additional Non-Executive Independent Director for a term of five years.
These appointments are expected to bring diverse expertise to the company’s governance and strategic direction.
Reconstitution of Board Committees
In consequence of the new director appointments, the Board also approved the reconstitution of its committees. The Audit Committee and the Stakeholders Relationship Committee have been reconfigured, with the updated compositions effective from August 11, 2026. Detailed disclosures regarding the reconstituted committee compositions have been provided.
Source: BSE
